{"id":21186,"date":"2025-01-10T22:40:31","date_gmt":"2025-01-10T14:40:31","guid":{"rendered":"https:\/\/flcube.com\/?p=21186"},"modified":"2025-01-10T22:40:33","modified_gmt":"2025-01-10T14:40:33","slug":"boehringer-ingelheim-licenses-adc-technology-from-synaffix-to-boost-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21186","title":{"rendered":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland&#8217;s Lonza (<a href=\"https:\/\/www.google.com\/finance\/quote\/LONN:SWX\">SWX: LONN<\/a>). This strategic deal is expected to significantly enhance Boehringer&#8217;s ADC portfolio, driven by its subsidiary, NBE Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Agreement Details<\/strong><br>Under the terms of the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated upon signing, with additional targets to be nominated within a predefined timeframe. In addition to an upfront payment, Synaffix is eligible to receive potential additional milestone payments of up to USD 1.3 billion, plus additional royalty payments on net sales of resulting products.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Synaffix&#8217;s Technology and Expertise<\/strong><br>Synaffix, a biotech company focused on the development of best-in-class ADCs, boasts a clinically validated ADC platform technology. This technology utilizes enzymatic modification of natural glycosyl anchor sites on antibodies to develop best-in-class ADCs or bispecific antibodies (BsAbs). The partnership with Boehringer Ingelheim will leverage Synaffix&#8217;s innovative platform to advance the development of novel therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Significance of the Partnership<\/strong><br>This partnership between Boehringer Ingelheim and Synaffix underscores the commitment of both companies to advancing innovative treatments in the field of oncology. By combining Synaffix&#8217;s cutting-edge ADC technology with Boehringer&#8217;s development and commercialization capabilities, the collaboration aims to bring new and effective therapies to patients in need.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":21189,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[35,390,16,678,3115,1842,826],"class_list":["post-21186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-boehringer-ingelheim","tag-cancer","tag-lonza","tag-nbe-therapeutics","tag-swx-lonn","tag-synaffix-b-v"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland&#039;s Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer&#039;s ADC portfolio, driven by its subsidiary, NBE Therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21186\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio\" \/>\n<meta property=\"og:description\" content=\"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland&#039;s Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer&#039;s ADC portfolio, driven by its subsidiary, NBE Therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21186\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T14:40:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-10T14:40:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"564\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio\",\"datePublished\":\"2025-01-10T14:40:31+00:00\",\"dateModified\":\"2025-01-10T14:40:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1019.png\",\"keywords\":[\"ADC \\\/ XDC\",\"Boehringer Ingelheim\",\"Cancer\",\"Lonza\",\"NBE Therapeutics\",\"SWX: LONN\",\"Synaffix B.V.\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21186#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21186\",\"name\":\"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1019.png\",\"datePublished\":\"2025-01-10T14:40:31+00:00\",\"dateModified\":\"2025-01-10T14:40:33+00:00\",\"description\":\"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland's Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21186\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1019.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1019.png\",\"width\":1080,\"height\":564,\"caption\":\"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21186#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland's Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21186","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio","og_description":"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland's Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics.","og_url":"https:\/\/flcube.com\/?p=21186","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-10T14:40:31+00:00","article_modified_time":"2025-01-10T14:40:33+00:00","og_image":[{"width":1080,"height":564,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21186#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21186"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio","datePublished":"2025-01-10T14:40:31+00:00","dateModified":"2025-01-10T14:40:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21186"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21186#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","keywords":["ADC \/ XDC","Boehringer Ingelheim","Cancer","Lonza","NBE Therapeutics","SWX: LONN","Synaffix B.V."],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21186#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21186","url":"https:\/\/flcube.com\/?p=21186","name":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21186#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21186#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","datePublished":"2025-01-10T14:40:31+00:00","dateModified":"2025-01-10T14:40:33+00:00","description":"German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland's Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21186#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21186"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21186#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","width":1080,"height":564,"caption":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21186#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1019.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21186"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21186\/revisions"}],"predecessor-version":[{"id":21190,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21186\/revisions\/21190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21189"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}